Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Syon Capital LLC

Syon Capital LLC cut its stake in Fresenius Medical Care AG (NYSE:FMS) by 12.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,530 shares of the company’s stock after selling 2,301 shares during the period. Syon Capital LLC’s holdings in Fresenius Medical Care were worth $323,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Advisor Partners II LLC boosted its holdings in Fresenius Medical Care by 16.3% during the third quarter. Advisor Partners II LLC now owns 10,836 shares of the company’s stock worth $233,000 after buying an additional 1,518 shares in the last quarter. Inspire Investing LLC acquired a new position in Fresenius Medical Care in the 3rd quarter worth approximately $600,000. First Trust Direct Indexing L.P. boosted its stake in Fresenius Medical Care by 6.6% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 23,888 shares of the company’s stock worth $515,000 after purchasing an additional 1,482 shares during the period. Signaturefd LLC boosted its stake in Fresenius Medical Care by 7.3% in the 3rd quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock worth $185,000 after purchasing an additional 584 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Fresenius Medical Care by 10.2% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 18,652 shares of the company’s stock worth $402,000 after purchasing an additional 1,732 shares during the period. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Stock Down 0.5 %

Fresenius Medical Care stock opened at $20.10 on Friday. The company has a market capitalization of $11.80 billion, a P/E ratio of 21.85, a P/E/G ratio of 1.10 and a beta of 1.00. The firm’s fifty day simple moving average is $19.51 and its 200-day simple moving average is $19.45. The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $27.72.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.36 by $0.11. The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. Sell-side analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Monday, June 3rd. Shareholders of record on Monday, May 20th will be given a $0.437 dividend. The ex-dividend date is Friday, May 17th. This represents a yield of 2.35%. Fresenius Medical Care’s dividend payout ratio is 45.65%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Morgan Stanley lowered shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research note on Monday, January 8th. StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Friday. They issued a “strong-buy” rating for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.